The federal government negotiated discounted prices for weight-loss drugs for state Medicaid programs, opened the door to states in the spring, and set a closing date. Its own model page still lists the number of participants as not applicable.
That gap between a federal pledge and actual coverage is the practical story for Medicaid enrollees who have been waiting to hear whether their state will cover a GLP-1 for obesity. The BALANCE Model, run by the Centers for Medicare and Medicaid Services, allows CMS to negotiate drug prices with drugmakers on behalf of states and Medicare Part D plans. Participation is voluntary for manufacturers, states, and plans, and that word is doing most of the work.
According to the BALANCE Model page, state Medicaid agencies can join between May 2026 and January 1, 2027. The page was last updated in mid-August, and it does not name a single participating state.
A Voluntary Model with a Closing Window
The model exists because federal law treats obesity drugs differently from other medications. Under the Medicaid Drug Rebate Program, states must cover nearly all of a participating manufacturer's approved drugs for medically accepted indications, but federal law gives states the option on drugs used for weight loss. Every state covers GLP-1s for type 2 diabetes. Coverage for obesity alone is a choice.
BALANCE was designed to make that choice cheaper. CMS lists the covered products as all formulations of Mounjaro, Ozempic, Rybelsus, and Wegovy; the KwikPen formulation of Zepbound; and Foundayo, all made by Eli Lilly or Novo Nordisk. The negotiations cover guaranteed net pricing, standardized coverage criteria, and lifestyle support, and enrollees receiving the drugs for weight management get a manufacturer-funded lifestyle program at no cost.
Abe Sutton, director of the CMS Innovation Center, framed the goal in the agency's announcement of the model. "CMS will make GLP-1s more accessible for people with Medicare and Medicaid," he said.
The Medicare half of the plan has already been rerouted. CMS delayed implementation of BALANCE in Part D and extended a separate short-term program, the Medicare GLP-1 Bridge, through the end of 2027. Under that demonstration, eligible Medicare beneficiaries pay $50 per month for medication.
The Coverage Map Has Been Shrinking, Not Growing
The reason a voluntary discount may not translate into coverage becomes clearer alongside what states have been doing on their own.
KFF counted 13 state Medicaid programs covering GLP-1s for obesity under fee-for-service as of January 2026, down from 16 states the previous fall, after California, New Hampshire, Pennsylvania and South Carolina ended coverage effective January 1. North Carolina removed coverage last year and then reinstated it. Since then, other states have weighed whether to drop coverage as well.
The direction of travel matters more than any single number. A discount is attractive to a state that wants to cover a drug and is worried about the price. It is less persuasive to a state that has just cut the benefit to close a budget gap, because a lower price on an optional benefit is still new spending.
The spending trend explains the pressure. In 2024 there were 8.4 million Medicaid prescriptions for GLP-1s and $8.6 billion in gross spending, both far above 2019 levels, according to KFF's analysis of federal utilization data. Those figures include diabetes and cardiovascular uses that states must cover, so they are not a measure of obesity coverage alone, but they describe the budget line that state officials are watching.
Who Is Left Waiting
The people most affected are Medicaid enrollees with obesity and no qualifying second diagnosis. Someone with type 2 diabetes, established cardiovascular disease, moderate to severe sleep apnea, or noncirrhotic MASH may have a covered pathway in any state, because federal rules treat those as medically accepted indications. Someone whose only indication is weight management depends entirely on where they live.
Geography is doing a lot of the work here, and it does not track need. KFF has reported that nearly 40 percent of adults and about a quarter of children covered by Medicaid have obesity.
There is also a group at particular risk of disruption: patients in the four states that ended coverage this year who had already started treatment. Stopping a GLP-1 generally leads to weight regain, and a change in coverage is not a clinical decision.
Practical Steps for Patients on Medicaid
No one should assume a federal announcement has changed their benefit. Coverage is set by each state, varies between fee-for-service and managed care, and shifts with budget cycles.
The most reliable check is a direct one. Enrollees can call the number on their Medicaid card or contact their state Medicaid pharmacy program to ask whether GLP-1s are covered for weight management, what the prior authorization criteria are, and whether the state has joined BALANCE. A prescriber's office or a pharmacy can often confirm the same information more quickly.
Patients who qualify on another basis should ask their clinician whether a documented diagnosis of diabetes, cardiovascular disease, sleep apnea, or MASH applies to them, because that changes the coverage question entirely. Anyone facing a denial can ask about the appeals process, and manufacturer assistance programs exist for some patients.
No one should stop a prescribed medication because coverage information is unclear, and cash-pay or compounded sources marketed online carry their own risks that a prescriber should weigh first.
The next milestone is January 1, 2027, the close of the window for states to join. Whether any state announces participation before then is the thing to watch. MedicalDaily will report state participation announcements and coverage changes as they are made.
Key Questions Answered
What is the BALANCE Model? A voluntary CMS demonstration under which the agency negotiates lower prices on certain GLP-1 medications with manufacturers on behalf of state Medicaid agencies and Medicare Part D plans.
Does it guarantee anyone coverage? No. CMS states plainly that coverage depends on participation by manufacturers and states, and that patients would still be subject to prior authorization requirements.
How many states have joined? The CMS model page lists the number of participants as not applicable. No participating states have been publicly named.
What is the deadline? State Medicaid agencies can join the model from May 2026 through January 1, 2027.
Which states cover GLP-1s for obesity now? KFF counted 13 state Medicaid programs as of January 2026, down from 16 the previous fall, after four states ended coverage effective January 1.
Is diabetes coverage affected? No. GLP-1 coverage for federally recognized indications, including type 2 diabetes, is required. The optional piece covers weight loss only.
What should an enrollee do right now? Contact the state Medicaid program or the number on the Medicaid card to confirm current coverage and prior authorization rules, and speak with a prescriber before making any changes.
